Specialty generic pharmaceutical company Sun Pharma announced earlier this week that it had received US Food & Drug Administration (FDA) approval for its New Drug Application (NDA) related to BromSite™ (bromfenac ophthalmic solution) 0.075% for the treatment of post-operative inflammation and prevention of ocular pain in patients undergoing cataract surgery.
BromSite is reportedly the first non-steroidal anti-inflammatory drug (NSAID) approved by the FDA to help prevent pain and treat inflammation in cataract surgery patients. Sun Pharma's newly-formed US division, Sun Ophthalmics, will reportedly commercialize and likely launch BromSite in the United States in the second half of 2016.
Click here to read the full press release.